BPI-572270 enters clinical trials.

A new company will develop “next-generation mRNA” projects, amid another mRNA setback.

But it will be up to doctors whether to use the combo in Darzalex-exposed patients.

Persevera is a bust, but Roche hasn’t given up on the front line.

Ono's antisense therapy is to begin its first pivotal trial.

Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.